Results per Page:
Understanding Parkinsonism after CAR T therapy
From Drs. John Sanderson, Kimmy Su, Anny Lin, and Yujie Wang, University of Washington Department of Neurology and Dr. Rahul Banerjee, Clinical Research Division
(TGF)Bait and Switch: Rewiring suppression into T cell power
From the Greenberg Lab, Translational Science and Therapeutics Division
RNA “typos” can highlight leukemia cells for immune attack
Looking beyond DNA, scientists find possible “surgically targeted” option for splicing factor-mutant blood cancers that lack effective immunotherapies
A quarter century of lifesaving discoveries in prostate cancer
Pacific Northwest Prostate Cancer SPORE insights have transformed patient care and understanding of prostate cancer biology, supported drug discovery worldwide
Detecting, detecting! A qPCR assay to detect WPRE sequences in CAR-T and TCR-T cells
From the Yeung lab, Translational Science and Therapeutics and Clinical Research Division
Extending efficacy for CAR T-cell therapies
Dr. Shivani Srivastava receives NCI MERIT Award to investigate how to improve engineered cancer immunotherapies against solid tumors through reservoirs of self-renewing immune cells
Dr. Phil Greenberg becomes president-elect of American Association for Cancer Research
Immunologist looks ahead to international leadership role
Send in the CARs: mesothelin-targeted CAR T cells against AML
From the Meshinchi Lab, Clinical Research Division, and Cancer Consortium colleagues
Investment in business development pays dividends for research, patients
Fred Hutch tech transfer specialists help scientists navigate path to bringing innovations to patients
Remodeling the tumor microenvironment for improved CAR T-cell therapy
From the Riddell and Srivastava Labs, Clinical Research Division
If at first you don’t succeed: Testing outcomes of second CAR T-cell infusions
From the Turtle group and collaborators, Clinical Research Division
Rewiring T cell death signaling enhances T cell function and persistence
From the Greenberg lab, Clinical Research Division
Antiviral immunity survives CD19-directed therapy
From the Hill and Turtle laboratories, Vaccine and Infections Disease Division and Clinical Research Division
Immunotherapy prevents relapse in small leukemia trial
Engineered T cells kept leukemia from returning in 12 high-risk patients
“Exciting” but early results in trial of immunotherapy for myeloma
Cancer cells disappeared rapidly in patients with high-risk, treatment-resistant disease
Immunotherapy strategy for ovarian cancer aims to rewire a ‘kill switch’ to ramp-up signal
T cells bearing a new engineered protein boost immunotherapy’s effectiveness in laboratory models of AML, ovarian, pancreatic cancers
First systematic study of infections after CAR T-cell therapy
“Benchmark” research could help reduce complications of emerging immunotherapy
Forum at Fred Hutch focuses on the hottest developments in cancer immunotherapy
Immune-based treatments move from the fringes to the spotlight
5 researchers receive awards to explore immunotherapy single-cell RNA sequencing
Projects accelerate Hutch position as early adopter of scRNA-seq technology
A Q&A with immunotherapy researcher Dr. Rachel Perret
As part of a world-class immunotherapy research team, Perret is working her ‘dream job’ — trying to bring T-cell therapy to all who need it